Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
21
×
boston blog main
fda
21
×
life sciences
21
×
national blog main
boston top stories
biotech
clinical trials
national top stories
deals
new york blog main
san francisco blog main
investing
new york top stories
san diego blog main
drugs
san diego top stories
san francisco top stories
alnylam pharmaceuticals
patisiran
startups
hereditary transthyretin amyloidosis
medical device
rna interference
roche
akcea therapeutics
inotersen
medical devices
onpattro
perceptive advisors
tafamidis
venture capital
alexion pharmaceuticals
biotech ipos
boston university
clinical trial
drug delivery
eli lilly
european medicines agency
eventide asset management
What
drug
fda
medicine
medicines
million
pharmaceuticals
alnylam
company
developing
device
ipo
new
therapeutics
way
approved
medical
patients
raised
rna
rnai
roche
startup
treat
acquire
ago
approval
biotechs
blood
body
candidate
cells
closed
deal
digital
disease
disorder
gene
interference
ipos
lead
Language
unset
unknown
Current search:
fda
×
" life sciences "
×
boston
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Renovia Raises $42M to Back Digital Treatment for Incontinence
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
@xconomy.com
6 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine